Skip navigation

Integrating Novel Technologies, Strategies & Cross-Functional Approaches to Accelerate Development & Compress Timelines

October 17-18, 2018
  • San Francisco, CA

To achieve ideal timelines, you must accelerate every individual function and handoff utilizing a precise blend of innovative technologies, proven strategies and exceptional project management. The right combination will enable you to successfully go from transfection to IND in less than 12 months. This ambitious goal requires a true team effort from every department.

CBI’s Speed to IND for Biologics provides a comprehensive, cross-functional format that brings together experts from every department to share their perspectives, achievements and lessons learned as a community working towards the common goal of accelerating speed while managing and mitigating risk.

Take Part in this Interactive Forum to Discuss and Determine the Best Approaches To:

  • Accelerate the Transition from R&D to Development
  • Address Cell Line Development Needs Using New Technologies and
    Alternate Strategies
  • Overlap Activities to Compress Timelines
  • Determine Best Technologies in Analytical and Process Sciences that
    Enable Compressed Timelines
  • Accelerate Development of New Modalities and Approaches
    to IND Filing
  • Integrate a Cross-Functional Approach to Successfully Manage
    Critical Path to IND
  • Determine and Mitigate the Technical, Manufacturing and
    Regulatory Risks
  • Address Regulatory and Quality Challenges in Accelerating Timelines


It will be great to compare notes with industry
thought-leaders on the opportunities and challenges
of accelerating biologics development.

President and CEO, Just Biotherapeutics, Inc.

This conference brings together hot topics, key opinion leaders and experts — I am looking forward to learning how the industry is adapting to the realities of today’s environment!

Senior Director, Protein and Cell Sciences, EMD Serono, Inc.

Attending CBI’s Speed to IND for Biologics presents a valuable opportunity to share experiences and bring back the lessons learned from the scientific community to our development team. In this way, we can further refine our approach of developing and transferring robust and scalable processes with the
aim to reduce timelines and mitigate risk.

Development Scientist I, Alexion Pharmaceuticals, Inc.

Regulatory strategies and experiences will be shared and discussed including how to address difficult to
“prove” legacy clonal cell lines.

Associate Research Fellow, Bioprocess R&D, Pfizer Inc

Speed to clinic, including how it is achieved, is one of the key drivers in a biologic’s lifecycle. It impacts everyone in the industry. It’s about time that this topic had a forum
for deep and vibrant discussion.

President, Latham Biopharm Group

I am excited to meet industry leaders who want to push
the boundaries of current practice for bringing
biologics to the patients.

Biologics Expert, Novartis, Switzerland

A New Community, Built for You

CBI BioProcessing Series icon CBI’s Bioprocessing Series has been strategically designed to unite developers and end users to collaborate and examine emerging trends, uncover new opportunities and overcome key challenges to successfully develop and produce the next wave of biotherapeutics.

Each event will serve as a platform to unite leading experts from every department and stage of development, to collectively tackle specific challenges in one room — not separated into several tracks with a tradeshow-like setup.

This streamlined approach paves the way for a variety of interactive formats that will encourage participation and maximize the conference experience for every attendee.